What is the 13F Pro Quality Score for EXEL?

13F Pro ranks EXELIXIS, INC. (EXEL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EXEL's current score at https://13fpro.ai/company/EXEL (free sign-up required for the full ranking).

Where does 13F Pro source EXEL data?

All EXELIXIS, INC. fundamentals and ownership data come directly from SEC EDGAR. EXELIXIS, INC. files with the SEC under CIK 939767. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EXEL in?

EXELIXIS, INC. (EXEL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives EXEL's revenue?

Per EXELIXIS, INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: Net product revenues ($573.0M, +10% YoY); CABOMETYX ($570.6M, +10% YoY); License revenues ($59.8M, +21% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/EXEL.

What are EXEL's largest expenses?

EXELIXIS, INC.'s latest 10-Q reports these as the largest expense items: Research and development ($212.0M, +6% YoY); Selling, general and administrative ($147.6M, +9% YoY); Cost of goods sold ($20.7M, +6% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is EXEL research updated on 13F Pro?

EXEL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

EXELIXIS, INC.(EXEL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 939767 EXEL stock profile & AI dashboard →

13F Pro Quality Score

76.2/100

Rank #87 of 2,960 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

59.9/100

Profitability

95.4/100

Balance Sheet

98.7/100

Earnings Quality

71.0/100

Free Cash Flow

94.3/100

Institutional Flow

63.1/100

Revenue Scale

66.1/100

Dilution Risk

25.1/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EXEL Scores 76/100

exact factor attribution · 2026-09-10

EXEL's composite is driven by profitability and free cash flow, held back by shareholder dilution. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+6.8 pts

95th pct

Free cash flow

+6.6 pts

94th pct

Capital efficiency

+4.9 pts

99th pct

Scale

+2.4 pts

66th pct

Earnings quality

+2.1 pts

71th pct

Revenue growth

+2.0 pts

60th pct

Earnings growth

+1.9 pts

89th pct

Institutional flow

+0.7 pts

63th pct

Shareholder dilution

-1.3 pts

25th pct

Latest change (2026-08-05): 79 → 76 · ↓ Revenue growth 74→51; ↓ Earnings growth 93→77; despite ↑ Institutional flow 48→58

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

EXEL Stock Analysis & AI Quality Score

Data updated 2026-09-10

AI stock analysis and institutional research for EXELIXIS, INC. (EXEL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EXEL at 76.2/100 on a 32-signal composite quality model, placing it at rank #87 of 2,960 stocks — the top 5% of the AI-ranked universe. EXEL scores in the top quartile across balance sheet strength (98.7), profitability (95.4), free cash flow (94.3). Shareholder dilution risk is elevated at 25.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), EXELIXIS, INC. reports quarterly revenue of $628.7M, net income of $212.1M, an operating margin of 39.5%. Top institutional holders of EXEL by reported 13-F value include BlackRock, FARALLON CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. EXEL trades on the Nasdaq exchange and files with the SEC under CIK 939767. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EXEL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for EXELIXIS, INC. directly from SEC EDGAR. EXELIXIS, INC.'s 13F Pro composite quality score has ranged between 51 and 83 since 2021, currently 76.2 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about EXELIXIS, INC.

Quirks, history, and lore behind EXEL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-to-mid cap · listed on Nasdaq · headquartered in Northern California.
2
The Numbers
Annual revenue in the range of roughly $1–2 billion, driven almost entirely by a single blockbuster drug — a remarkably concentrated bet for a public company.
3
The History
Founded in the late 1990s as a genomics-era startup, it pivoted hard into oncology and spent years in clinical-stage purgatory before finally hitting gold.
4
The Secret
Its core expertise is kinase inhibitor chemistry — molecules that jam the signaling switches cancer cells rely on to grow and spread.
5
The Lore
Its lead compound targets the MET and VEGFR2 pathways and has won approvals across multiple tumor types, including kidney and thyroid cancers — a rare multi-indication win for a small biotech.
6
The Giveaway
One word: cabozantinib — sold as Cabometyx — the kinase inhibitor that turned this genomics relic into a genuine oncology powerhouse.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving EXEL's Business? Latest 10-Q Breakdown

✓ 26/26 datapoints verified

AI-extracted from EXELIXIS, INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenues rose 11% to $628.7M as CABOMETYX net product revenues grew 10% to $570.6M on 6% unit growth, lifting net income to $212.1M ($0.82 diluted).

Biggest Revenue Drivers

Net product revenues$573.0M+10% YoY

6% increase in CABOMETYX units sold plus a 4% increase in average net selling price

License revenues$59.8M+21% YoY

Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M

Biggest Revenue Drivers

Total revenue: $628.7M+11% YoY

Net product revenues$573.0M+10% YoY

6% increase in CABOMETYX units sold plus a 4% increase in average net selling price

Within Net product revenues

CABOMETYX$570.6M+10% YoY

Continuing demand in combination with nivolumab in first-line advanced RCC and demand in previously treated advanced NET

License revenues$59.8M+21% YoY

Increases in Ipsen's net sales of cabozantinib outside the U.S. and Japan; Ipsen royalties were $50.5M

Collaboration services revenues-$4.1M+293% YoY

Lower development cost reimbursements and higher 3% royalties paid to Royalty Pharma on partner sales

Largest Expense Items

Research and development$212.0M+6% YoY

Higher clinical trial costs for zanzalintinib, XB371 and XB628, manufacturing and license costs, offset by lower personnel expense

Selling, general and administrative$147.6M+9% YoY

Increased marketing for zanzalintinib pre-launch activities and higher personnel expenses

Cost of goods sold$20.7M+6% YoY

Higher royalties from increased U.S. CABOMETYX sales

Margins: Gross margin held at 96%, unchanged from the prior-year quarter, and management projects gross margin will not change significantly during the remainder of 2026.

Watch Items from the Filing

Generic/505(b)(2) filers MSN, Azurity, Handa, Accord and Almatica challenge CABOMETYX patents; consolidated trial set November 2, 2026, and FDA gave Handa tentative approval July 29, 2026.
Five customers each exceed 10% of revenue: McKesson 21%, Cencora 20%, CVS 15%, Accredo 10%, Cardinal Health 10%.
Zanzalintinib NDA in colorectal cancer has a PDUFA date of December 3, 2026; the NLM subgroup endpoint missed statistical significance (HR 0.83, P=0.1185).
Repurchased 20.2M shares for $902.2M under buyback programs; cash and marketable securities fell to $1.4B from $1.7B at December 31, 2025.
Future in-licensing obligations include up to $441.5M development, $278.0M regulatory and $2.5B commercial milestone payments.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$628.7M

Net Income

Q2 2026

$212.1M

Free Cash Flow

Q2 2026

$300.9M

Operating Margin

Q2 2026

39.5%

ROIC

Q2 2026

53.9%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+7.0% YoY

$2.32BFY 2025

FY22 $1.61BFY23 $1.83BFY24 $2.17BFY25 $2.32B

Net Income

+50.1% YoY

$782.6MFY 2025

FY22 $182.3MFY23 $207.8MFY24 $521.3MFY25 $782.6M

Operating Income

+44.3% YoY

$872.2MFY 2025

FY22 $201.5MFY23 $170.9MFY24 $604.6MFY25 $872.2M

EPS (Diluted)

+58.0% YoY

$2.78FY 2025

FY22 $0.56FY23 $0.65FY24 $1.76FY25 $2.78

Total Assets

-3.5% YoY

$2.84BFY 2025

FY22 $3.07BFY23 $2.94BFY24 $2.95BFY25 $2.84B

Op. Cash Flow

+26.3% YoY

$884.3MFY 2025

FY22 $362.6MFY23 $333.3MFY24 $700.0MFY25 $884.3M

Free Cash Flow

+30.4% YoY

$875.8MFY 2025

FY22 $334.9MFY23 $292.9MFY24 $671.5MFY25 $875.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.32B +7.0%	$2.17B +18.5%	$1.83B +13.6%	$1.61B +12.3%	$1.43B +45.3%	$987.5M
Net Income	$782.6M +50.1%	$521.3M +150.9%	$207.8M +14.0%	$182.3M -21.1%	$231.1M +106.7%	$111.8M
Operating Income	$872.2M +44.3%	$604.6M +253.8%	$170.9M -15.2%	$201.5M -29.7%	$286.7M +160.5%	$110.1M
EPS (Diluted)	$2.78 +58.0%	$1.76 +170.8%	$0.65 +16.1%	$0.56 -22.2%	$0.72 +105.7%	$0.35
Total Assets	$2.84B -3.5%	$2.95B +0.2%	$2.94B -4.2%	$3.07B +17.4%	$2.62B +22.4%	$2.14B
Operating Cash Flow	$884.3M +26.3%	$700.0M +110.0%	$333.3M -8.1%	$362.6M -9.5%	$400.8M +91.8%	$209.0M
Free Cash Flow	$875.8M +30.4%	$671.5M +129.3%	$292.9M -12.6%	$334.9M -3.4%	$346.6M +94.0%	$178.6M

Get alerted when EXEL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for EXELIXIS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EXEL

BlackRock, Inc.
$1.6B29,075,377 sh
FARALLON CAPITAL MANAGEMENT LLC
$732.8M13,468,010 sh
RENAISSANCE TECHNOLOGIES LLC
$730.6M13,427,993 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$655.3M12,043,122 sh
AQR CAPITAL MANAGEMENT LLC
$598.6M11,023,943 sh
VANGUARD CAPITAL MANAGEMENT LLC
$595.8M10,950,997 sh
STATE STREET CORP
$542.5M9,970,071 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$485.8M8,929,389 sh
LSV ASSET MANAGEMENT
$443.3M8,146,478 sh
GEODE CAPITAL MANAGEMENT, LLC
$416.3M7,650,316 sh

Fund	Value	Shares
BlackRock, Inc.	$1.6B	29,075,377
FARALLON CAPITAL MANAGEMENT LLC	$732.8M	13,468,010
RENAISSANCE TECHNOLOGIES LLC	$730.6M	13,427,993
VANGUARD PORTFOLIO MANAGEMENT LLC	$655.3M	12,043,122
AQR CAPITAL MANAGEMENT LLC	$598.6M	11,023,943
VANGUARD CAPITAL MANAGEMENT LLC	$595.8M	10,950,997
STATE STREET CORP	$542.5M	9,970,071
FULLER & THALER ASSET MANAGEMENT, INC.	$485.8M	8,929,389
LSV ASSET MANAGEMENT	$443.3M	8,146,478
GEODE CAPITAL MANAGEMENT, LLC	$416.3M	7,650,316

Companies Similar to EXEL

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

NBIX

NEUROCRINE BIOSCIENCES INC

AI score

Very similar · 28 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Swedbank AB FULLER & THALER ASSET MANAGEMENT, INC.

UTHR

UNITED THERAPEUTICS Corp

AI score

Very similar · 29 shared holders

LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

INCY

INCYTE CORP

AI score

Very similar · 32 shared holders

LSV ASSET MANAGEMENT CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Robeco Institutional Asset Management B.V.

JAZZ

Jazz Pharmaceuticals plc

AI score

Very similar · 21 shared holders

LSV ASSET MANAGEMENT FULLER & THALER ASSET MANAGEMENT, INC.Swedbank AB

MEDP

Medpace Holdings, Inc.

AI score

Similar quality profile · 32 shared holders

FULLER & THALER ASSET MANAGEMENT, INC.Stephens Investment Management Group LLC CAISSE DE DEPOT ET PLACEMENT DU QUEBEC

RMD

RESMED INC

AI score

Similar quality profile · 25 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Swedbank AB VOLORIDGE INVESTMENT MANAGEMENT, LLC

IDXX

IDEXX LABORATORIES INC /DE

AI score

Similar quality profile · 12 shared holders

CAISSE DE DEPOT ET PLACEMENT DU QUEBEC Stephens Investment Management Group LLC Robeco Institutional Asset Management B.V.

DXCM

DEXCOM INC

AI score

Similar quality profile · 15 shared holders

Stephens Investment Management Group LLC Swedbank AB Bridgewater Associates, LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EXEL on your watchlist

Track score changes the day EXELIXIS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EXEL a good stock to buy?

13F Pro's AI-powered analysis of EXELIXIS, INC. (EXEL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EXEL are available on the EXEL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EXEL is classified as a large company.

Which hedge funds own EXEL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EXEL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of EXELIXIS, INC.'s investment landscape.